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Abstract
Purpose: To demonstrate the utility of a boost with interstitial brachytherapy (BT) in breast-conserving therapy 
(BCT) by doing a thorough review of the literature and describing in detail our technique for delivering this boost.
Material and methods: Our department has been delivering the boost with interstitial BT since 1989, in most cas-
es with rigid needles and a theoretical dosimetry. In the early years, we used low-dose-rate (LDR) with iridium-192 
wires. The dose administered was 15 Gy if there were no risk factors for local relapse or 20-25 Gy in the presence of risk 
factors. The risk factors considered were the presence of a close margin (less than 10 mm) and an extensive intraductal 
component (more than 25%). After 2002, we switched to high-dose-rate (HDR); using the linear quadratic model we 
changed the low dose to 3 fractions of 4.5 Gy in the case of no risk factors for local relapse or to 3 fractions of 5 Gy in 
the presence of risk factors. 
Results: In 79 consecutive boost patients treated in our department between 2010 and 2011, with a median fol-
low-up of 46 months, the local control rate was 97.47%. With respect to cosmesis, fibrosis occurred in 17 cases (21.5%) 
and hyperpigmentation in 26 cases (32.9%). Our hospital’s results are comparable in terms of local control and cosmesis 
to those of other authors.
Conclusions: This educational article describes our department’s boost technique with rigid needles and comments 
briefly on our results using this technique in a group of consecutively treated patients in our department. A review of 
the literature and the published results on local control and cosmesis is also described.
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Purpose
In the conservative treatment of breast cancer, the util-
ity of the boost has been clearly shown in several publica-
tions. Because of the trial design, the strongest publication 
is the boost versus no boost trial from the European Orga-
nisation for Research and Treatment of Cancer (EORTC) 
[1,2]. Brachytherapy is an excellent way of delivering this 
boost, especially in patients at high risk for local recurrence 
[3]. A Hungarian randomized trial by Polgar et al. in 2002, 
also showed that a boost dose significantly improves local 
control, and that this is especially important for patients at 
high risk for local recurrence, such as patients with posi-
tive or close margin status, high mitotic activity index, and 
young age. Local control and cosmesis were shown to be 
excellent and similar in patients boosted with either high-
dose-rate brachytherapy (HDR-BT) or electrons [4]. In our 
hospital, about 90% of patients diagnosed with breast can-
cer receive breast-conserving therapy (BCT). Every year we 
treat more than 600 patients with breast cancer, and after 
receiving 50 Gy to the whole breast they need a boost to 
the tumour bed. Our Brachytherapy Unit was opened in 
1989, and since then we have frequently been treating pa-
tients with a BT boost. In the early years, we preferred to 
do the boost with an interstitial implant because we had 
limited access to the linacs. We needed the electrons from 
the linacs for head and neck patients, and therefore we 
only used electrons for the breast boost when BT could not 
be performed. Our experience in T1 breast tumours treat-
ed with 50 Gy to the whole breast plus a boost with low-
dose-rate (LDR) 192Ir has already been published in 2000 
[5]. Our department has extensive experience in this field 
and in this article we share our tips and tricks about how to 
perform the interstitial BT boost.
Material and methods
The external whole breast irradiation consists of 50 Gy 
to the isocenter or 45 Gy at 90% of the dose. We initially 
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used the photons from 60Co and then from 1995 started 
using 6 MV photons from a linear accelerator, until Janu-
ary 2004, when we definitively closed our cobalt unit. For 
the boost, in the early years, we did not perform image- 
guided BT: to localize the tumour bed we considered 
the preoperative mammography, the position of the scar, 
the surgical report, and the patient’s description if the 
nodule was palpable.
Brachytherapy was used in almost all cases, inde-
pendent of whether the tumour bed location was deep or 
superficial. In patients with superficial tumour beds and 
small breasts, only one plane was used, in most cases with 
plastic tubes. The distance between needles was 1.8 cm 
and a plastic template in the shape of equilateral triangles 
was used. Low dose rate was used with 192Ir wires and the 
dose administered was 15 Gy, if there were no risk factors 
for local relapse or 20-25 Gy in the presence of risk factors. 
The risk factors considered were the presence of a close 
margin (less than 10 mm) and extensive intraductal com-
ponent (more than 25%). Also for young women under 
40 years, higher doses were usually administered. In 2002 
the department switched to HDR. Using the linear quad-
ratic model and previous Spanish experience (Guinot) [6] 
with an α/β ratio of 10 for the tumor and 3 for the skin 
and fat tissue, we obtained the dose we are delivering with 
HDR. This dose is 3 fractions of 4.5 Gy, equivalent to 16 Gy 
with electrons, if there are no risk factors for local relapse. 
In the presence of risk factors, this dose is 3 fractions of 
5 Gy, equivalent to 20 Gy. The dose with HDR-BT is de-
livered in approximately 22 hours, the same timeframe in 
which LDR was delivered (at 0.5-0.7 Gy/h).
Today we are stricter with the eligibility criteria. The 
most suitable cases are patients with deep lesions in large 
breasts, but we also perform BT in small breasts, depend-
ing on the relationship between the cavity and the size of 
the breast. In the case of a small breast, a smaller implant 
would be performed using 5-7 needles, whilst in larger 
breasts 9 needles are usually used. With respect to the 
margin, 10 mm is considered a free margin, in which case 
we would administer 3 fractions of 4.5 Gy (equivalent to 
16 Gy at 2 Gy/fractions with electrons). In the other cases, 
we would administer 3 fractions of 5 Gy (equivalent to 
a 20 Gy with electrons). If the margin is clearly affected by 
tumour, we would perform a margin re-excision to obtain 
free margins. The size of the cavity is clearly important. 
An ultrasound (US) is always performed before the im-
plant to check if there is a seroma, and to identify the tu-
mour bed if possible. If identified, the tumour bed is mea-
sured. The maximum length should be 6 cm, in order to 
include all the seroma with a “9 hole” template implant.
Nowadays, oncoplastic surgery is becoming more 
popular and many patients are treated with different 
techniques. In our center, the surgeons always mark the 
surgical bed with clips. We always consider the location 
of the clips in the dosimetry computed tomography (CT) 
and carefully read the surgical report. In oncoplastic sur-
gery cases, there is typically no seroma present and BT is 
usually not performed due to the difficulty in localizing 
the tumour bed. It should be noted however, that it is also 
difficult to delineate the tumour bed for external beam 
radiotherapy (EBRT) in such cases.
In recent years, as the department has more electrons 
available, the following are also considered to evaluate if 
the patient is a good candidate for a BT boost: 1) the pa-
tient’s general condition, co-morbidities and other factors 
such as anticoagulant intake or heparin use; 2) the pa-
tient’s anatomy and the location of the surgical bed and 
the scar; 3) the CT scan for (EBRT) planning: the seroma 
can be clearly visualized in cases where a seroma exists; 
4) the preoperative mammography; 5) an US is also per-
formed during the course (of EBRT) to evaluate the sero-
ma and the skin distance; the distance must ideally be 
greater than 1 cm. If there is no seroma, we consider if 
there is enough tissue to do the implant and if clips are 
present in the surgical bed margins.
At our institution we strongly believe that BT is the 
best way of delivering the boost because the dose-inten-
sity is higher. Immediately after completing EBRT, 3 frac-
tions of 4.5 or 5 Gy are administered in less than 24 hours. 
Thus, the overall treatment time is really shortened com-
pared to those patients who receive 10 fractions of 2 Gy 
with electrons over a further 2 weeks. In addition, com-
pared to EBRT, the treated volume with BT is smaller, 
and the use of CT and US ensures delivery of the boost to 
the tumor bed. The distribution of the isodoses delivered 
with BT is also different to the ones obtained with EBRT: 
higher doses (hot spots) are obtained in the tumour bed 
with a rapid fall-off, respecting the skin if the superficial 
plane is at least 1 cm under the surface. For all the above 
reasons we firmly believe in BT and try to perform it in all 
patients who are suitable candidates.
In the Brachytherapy Unit we have one dedicated 
operating theatre with an anaesthesiologist. Four or five 
procedures are performed in one day. Deep sedation 
is administered for the patient’s comfort. Firstly, an US is 
performed to localize the tumour bed (Fig. 1) and pro-
ject it on to the skin (Fig. 2); a marker is used to draw it, 
and then the template is leaned on to the patient’s skin 
to mark the entrance and exit points in order to obtain Fig. 1. Ultrasound to localize the tumour bed (seroma)
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a good geometric distribution. We try to leave at least 
3 cm from the first point to the projection of the planning 
target volume (PTV). Local anaesthesia (2% Mepivacaine 
with a little bicarbonate) is injected at the entrance and 
exit points of every needle (Fig. 3). When doing the im-
plant, the ultrasound is used continuously to find the 
seroma and check the position of every needle with re-
spect to the seroma and to the skin. In cases without se-
roma, a CT is performed just before entering the operat-
ing theatre to look for the clips. We then try to surround 
the whole seroma with needles, always starting with the 
superficial plane. The first plane is inserted between the 
skin and the superficial part of the seroma (Fig. 4), and 
the deep plane under the seroma (Fig. 5). The free-hand 
technique is used for the superficial plane and the tem-
plate is used to guide the rest of the implant. The distance 
to the skin and the pectoral muscle is checked with US. 
In most cases, a 2-plane implant is sufficient. Many other 
centers start with the deep plane, but using the US we are 
able to adjust any of the needles as necessary. Some cen-
ters use the free-hand technique, others always use a tem-
plate. Some centers perform a CT before the implant and 
others use US; our instituion considers all techniques to 
be adequate, depending on the department experience.
The needles are not usually substituted for plastic 
tubes. Great care is taken to leave at least 1 cm between 
Fig. 3. Local anaesthesia in the entry and exit points  
of every needle
Fig. 2. Projection of the seroma on the skin
Fig. 5. Needle of the deep plane under the seromaFig. 4. Needle of the first plane between the skin and  
the superficial part of the seroma
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the superficial plane and the skin to avoid late toxicity 
in the form of telangiectasia. Metallic buttons are used 
to avoid longitudinal needle movement, and a metallic 
bridge is used to secure the needles (Figs. 6 and 7). In 
most cases, a theoretical dosimetry is done without CT 
scan. As the needles are metallic, we just measure the dis-
tance from the tip and the end of the needle to the PTV, 
and also the distance to the skin for every needle. We also 
check with US that there is more than 1 cm between the 
superficial plane and the skin.
The Oncentra® planning system (Elekta Brachyther-
apy, Elekta AB, Stockholm, Sweden) is used and for the 
dosimetry a modified Paris System is used. Every patient 
receives 3 fractions of 4.5 or 5 Gy with HDR from a Micro-
selectron HDR (Elekta Brachytherapy), separated by at 
least 6 hours. As our Brachytherapy Unit has 14 beds, the 
patient can stay in hospital overnight. The next morning 
the third fraction is given and after removal of the im-
plant the patient is discharged.
Results
Since many of our patients come from different hos-
pitals, we are unable to follow up all of them. However, 
for this study we have selected 79 consecutive patients 
who received their boost with BT in our department be-
tween June 2010 and June 2011 and attempted to per-
form a retrospective study looking at the clinical records 
of 4 different radiation oncologists. We considered any 
grade of hyperpigmentation or fibrosis that was de-
scribed by the different physicians. In this group, we 
describe our results in terms of local control and cos-
mesis. The median follow-up period was 46 months 
(range 36-57) and the mean follow-up was 45.8 months. 
The median treated volume (V100) was 94.49 cc (range 
35.8-190). At the end of the study, 8 patients had devel-
oped a relapse: 2 local relapses, 2 regional node metasta-
ses, and 7 distant metastases, resulting in a local control 
rate of 97.47%. Three patients died due to breast cancer 
at 15, 27 and 41 months.
With respect to cosmesis, fibrosis was observed in 
17 cases (21.5%), hyperpigmentation in 26 cases (32.9%), 
asymmetry in 3 cases (3.8%), and telangiectasia in 1 case 
(1.3%). One patient developed fat necrosis and 1 patient 
achromia at the entrance and exit points of the BT nee-
dles. Of course these rates change over time and we have 
not and were not able to register them actuarially. Other 
side effects included a radiation pneumonitis in 1 pa-
tient, which was successfully treated with corticosteroids, 
2 cases of mastitis, and 1 case of an abscess.
Complications can arise after BT, but these can usu-
ally be easily and successfully managed. Bleeding, either 
during insertion or removal of the needle, stops after 
compressing the area. Usually less than a minute of com-
pression is enough, but in some cases up to 3 minutes of 
compression may be necessary. If the patient is taking 
antiaggregants, it is recommended to stop them 5 days 
before surgery. Oral anticoagulants should be substituted 
by heparin. If there is an infection, oral antibiotics should 
be administered for 2 weeks. Fat necrosis is a late com-
plication that manifests as pain and inflammation of the 
surgical bed; it is a clinical diagnosis and infection must 
be ruled out. Fat neccrosis can also be identified on mam-
mography. Management with oral anti-inflammatories 
for several weeks is usually effective treatment, although 
in some cases evacuation of the fat necrosis may be nec-
essary.
Discussion
The use of an interstitial implant as a boost as part 
of BCT has been practiced for many years, especially 
in Europe. Van Limbergen describes the advantages of 
delivering the boost with BT in terms of improving lo-
cal control, probably due to the increased dose to the 
tumour bed. He discusses in detail the technical aspects 
of breast BT that appear to be relevant for a high quali-
ty clinical outcome, especially with respect to the skin in 
order to obtain a good cosmetic result [7]. Many authors 
have described their results in terms of local control and 
cosmesis. In 2000, our department published our results 
for T1 tumours in 530 patients who were treated with 
whole breast irradiation up to 50 Gy and a BT boost [5]. 
The mean BT dose was 16.8 Gy. With a median follow-up 
Fig. 7. Picture of another implant in the outer quadrantsFig. 6. Final picture of the rigid implant with the metallic 
bridge and the template
Journal of Contemporary Brachytherapy (2014/volume 6/number 4)
Breast interstitial boost in breast conserving therapy 401
of 39.5 months, the local control was 94.9% and 91.7% at 
5 and 7 years, respectively. Univariate analysis demon-
strated that age (older than 52 years), premenopausal sta-
tus, moderate and high histological grades (grades II-III), 
and presence of intraductal comedocarcinoma were prog-
nostic factors for local relapse. Multivariate analysis for lo-
cal disease-free survival demonstrated that only perineu-
ral or muscular infiltration remained as prognostic factors. 
A tumour bed dose of 70 Gy or higher had a negative im-
pact on breast subcutaneous fibrosis, whereas a dose rate 
lower than 65 cGy/h was better for skin colour at 2 years.
It is also known that BT is an excellent way of giv-
ing radiotherapy to a small volume. In the boost vs. no 
boost trial, with a boost of 16 Gy, the volume treated with 
BT was just 60 cc vs. 144 cc for electrons and 288 cc for 
photons [1]. The dose administered with BT was 15 Gy at 
a rate of 10 Gy/24 hours, and there was a median delay 
to administering the BT of 18 days, with a longer overall 
treatment time (54 vs. 48 days). It was evident that the 
rate of local relapse was even smaller in the BT group, 
despite a much smaller treatment volume and the longer 
overall treatment time. The differences, however, were 
not statistically significant. At 5 years, local recurrences 
were seen in 2.5% of the patients after an interstitial boost, 
in 4.8% of the patients who received an electron boost, 
and in 4% of the patients who received a photon boost. 
The grade of fibrosis in the whole breast as well as at the 
primary tumour bed was similar in the three groups. 
After a median follow-up period of 10.8 years, a boost dose 
of 16 Gy led to improved local control in all age groups, 
but no difference in survival [2]. During the 90’s, a lot of 
studies have focused on the aesthetic results, looking at 
whether the cosmestic outcome was better with electrons 
or with BT [8-11], but it still remains a controversial issue 
[12,13]. Few of these studies were randomized and most 
of them were a retrospective comparison between series 
even from different hospitals. This is reflected by Toboul 
et al. in 1995: in his study a small difference in cosmesis 
was noted in favour of patients that received an electron 
boost, but they received the EBRT to the whole breast 
with 4-6 MV photons from a linac; whilst the other group 
from another hospital received whole breast irradiation 
with 60Co and an 192Ir boost and had more axillary dis-
section. Interestingly, no differences in local control were 
found, despite the mean implanted volume being 31 cc 
with a mean delay of 26.6 days versus 118 cc with elec-
trons after a mean delay of 5.5 days [9].
A prospective randomized study was published by 
Fourquet et al. in 1995, comparing an 192Ir implant boost 
with a 60Co EBRT boost to the primary tumour site, in 
255 patients with tumours 3-7 cm in diameter, but in pa-
tients that were receiving definitive radiotherapy after 
a core biopsy only. The boost dose was 20 Gy in both 
groups. Cosmetic outcome in both groups was evaluated 
in 120 patients with a minimum 3-year follow-up and was 
comparable in both groups [14]. In 1997, Wazer et al. re-
ported a prospectively applied boost dose escalation to the 
tumour bed and concluded that interstitial implant boost 
for breast conserving irradiation was associated with bet-
ter cosmesis that EBRT boost, and that local control with 
implantation might be further enhanced by increasing 
implant volume and/or improved target localization [15].
In fact, no clear differences were actually found in any 
of the studies, as in the study from Perez et al., published 
in 1996. This study compared the results of the boost in 
449 patients with T1 and T2 breast cancer treated with 
9-12 MeV electrons versus 129 patients treated with an 
interstitial implant, 29 intraoperatively and 90 postopera-
tively. There was no significant difference in local tumour 
control, cosmesis or morbidity in patients treated with ei-
ther electron beam or interstitial 192Ir implant boost [8]. 
The adoption of either of the boost techniques basically 
depends on department experience. Nowadays, the use of 
BT as a boost may be limited to patients, as described by 
Perez, with deeply seated target volumes in large breasts 
more than 4 cm below the skin, with microscopically pos-
itive or unknown margins not undergoing re-excision, 
or with other poor pathologic features such as extensive 
intraductal component [8]. Perez’s study probably found 
no differences in local control according to the status of 
the margins because the patients with close or positive 
margins received a BT boost of 25 Gy.
In 1997, Vicini et al. reported their retrospective ex-
perience on 400 cases of stage I and II breast cancer, and 
also concluded that long-term local control and cosme-
tic outcome are excellent and similar in patients boosted 
with either electrons, photons or with LDR interstitial 
BT [16]. Frazier et al. reach the same conclusion in their 
study: no significant differences in the local recurrence 
rates or cosmetic outcome using electrons, photons, or an 
interstitial implant. On multivariate analysis, however, 
young age and margin status are found to be associated 
with increased local recurrence [17]. In 2010, Polgar et al. 
described their experience with HDR interstitial implant 
boost, either with rigid needles or plastic tubes [18]. After 
a median follow-up time of 94 months, only 7% ipsilateral 
breast failures were observed for a 5- and 8-year actuari-
al rate of 4.5% and 7.0%, respectively. Cosmetic outcome 
was rated excellent in 17%, good in 39%, fair in 33%, 
and poor in 11%. Grade 3 fibrosis and grade 3 telangiec-
tasia occurred in 6.6% and 2.2% patients, respectively. 
In a univariate analysis, only positive margin status had 
a significant negative effect on local control. Guinot et al. 
have also published their results with 3 fractions of 4.4 Gy 
HDR in a series of 125 women with less than 5 mm or pos-
itive margins. The actuarial local control rate was 95.8% 
at 5 years and 91.1% at 9 years. Late fibrosis was the most 
common complication in 30% of patients, with good or 
excellent cosmetic results in 77% [6]. Resch et al. reported 
their results in a large retrospective cohort study of 410 
women with early breast cancer treated with BCT including 
an interstitial BT boost. The treated volume was 104 cc for 
LDR-BT and 83 cc for HDR-BT. The 5- and 10-year actuar-
ial local recurrence rates were 2% and 3.9%, respectively. 
Only age and menopausal status had significant impact 
on local control. Their conclusion was that the high-dose 
and large-volume interstitial BT appears to be superior to 
classical BCT without BT [19].
For the BT boost, the dose rate has been noted to re-
late to differences in cosmesis and local control by sev-
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eral authors, while some noted a higher incidence of 
breast recurrences with a dose rate less than 0.3 Gy/h. 
Mazeron et al. observed increased 5-year local tumour 
control with dose rates higher than 0.5 Gy/h [20]. Bud-
rukkar et al. found that the type of tumour bed boost 
did not have a significant effect on cosmetic outcome, 
although there were significantly more late breast seque-
lae in women treated with single fraction HDR implants 
compared to LDR [21]. Harms et al., in a series of 113 pa-
tients, reported that PDR at 1 Gy/h is as effective as LDR 
for the boost [22]. Pieters et al. investigated the timing of 
the interstitial boost and concluded that the cosmesis was 
similar for the patients that received the boost per-oper-
atively compared to the patients that received it after the 
EBRT [23].
One of the studies with the longest follow-up period is 
the one published by Hill-Kayser et al. in 2011. It is a match-
ed 1 : 1 study of 141 patients treated with whole breast radio-
therapy followed by an 192Ir boost after breast-conserving 
surgery matched to patients treated with an electron boost. 
Twenty-year data demonstrated no difference in rates of 
local recurrence or patterns of failure between both groups. 
Better cosmesis was observed in the electron group 1 year 
after radiotherapy, with a trend continuing for 10 years. 
The incidence of complications was similar between the 
groups, with a trend towards increased fibrosis in patients 
receiving implant boost [24]. With a median follow-up of 
46 months, the local control rate in our department’s study 
is 97.47%. Our cosmetic results are fibrosis in 17 cases 
(21.5%) and hyperpigmentation in 26 cases (32.9%). These 
results are comparable in terms of local control and cosme-
sis to those from other authors.
A good conclusion to this discussion is the one from 
Hannoun-Levi: he suggests that only a phase III trial 
randomizing BT boost vs. electron therapy boost could 
show a possible improvement of local control rate in the 
BT arm. “However, this trial should enrol patients with 
a real high risk of local recurrence in order to take benefit 
from the dosimetric advantages of BT” [25].
Conclusions
We have described our department’s technique for 
the boost with rigid needles and commented briefly on 
our results with this technique in a group of consecutive-
ly treated patients. We have also reviewed the literature 
and the results published on local control and cosmesis.
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